Advertisement

Impact of somatic and germline mutations on the outcome of systemic mastocytosis

Javier I. Muñoz-González, María Jara-Acevedo, Iván Alvarez-Twose, Jason D. Merker, Cristina Teodosio, Yanli Hou, Ana Henriques, Krishna M. Roskin, Laura Sanchez-Muñoz, Albert G. Tsai, Carolina Caldas, Almudena Matito, J. Ignacio Sánchez-Gallego, Andrea Mayado, Noelia Dasilva-Freire, Jason R. Gotlib, Luis Escribano, Alberto Orfao and Andrés C. García-Montero

Article Information

Citation 
vol. 2 no. 21 2814-2828
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 7, 2018
  • Accepted October 1, 2018
  • Published online October 29, 2018.


Contributors 
  • Javier I. Muñoz-González, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;
  • María Jara-Acevedo, 2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;4Sequencing Service (NUCLEUS), University of Salamanca, Salamanca, Spain;
  • Iván Alvarez-Twose, 3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;5Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain;
  • Jason D. Merker, 6Department of Pathology, Stanford University School of Medicine, Stanford, CA;
  • Cristina Teodosio, 7Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands; and
  • Yanli Hou, 6Department of Pathology, Stanford University School of Medicine, Stanford, CA;
  • Ana Henriques, 3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;5Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain;
  • Krishna M. Roskin, 6Department of Pathology, Stanford University School of Medicine, Stanford, CA;
  • Laura Sanchez-Muñoz, 3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;5Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain;
  • Albert G. Tsai, 6Department of Pathology, Stanford University School of Medicine, Stanford, CA;
  • Carolina Caldas, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;
  • Almudena Matito, 3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;5Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain;
  • J. Ignacio Sánchez-Gallego, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;
  • Andrea Mayado, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;
  • Noelia Dasilva-Freire, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;
  • Jason R. Gotlib, 8Division of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA
  • Luis Escribano, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;
  • Alberto Orfao, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;
  • Andrés C. García-Montero, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), CIBERONC, University of Salamanca, Salamanca, Spain;2Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;3Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output